High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats

BMC Nephrology

Klaus Olgaard²  Ewa Lewin¹  Maria L Mace¹  Jacob Hofman-Bang²  Eva Gravesen² 

[1] Nephrological Department B, Herlev Hospital, Copenhagen, Denmark;Nephrological Department P, Rigshospitalet, University of Copenhagen, P 2132, 9 Blegdamsvej, Copenhagen DK 2100, Denmark

关键词: Chronic kidney disease;    Phosphate;    FGF23;    Iron;   

Others  :  1082758
DOI  :  10.1186/1471-2369-14-281

 received in 2013-10-17, accepted in 2013-12-24,  发布年份 2013

【 摘 要 】

Background

High iron load might have a number of toxic effects in the organism. Recently intravenous (iv) iron has been proposed to induce elevation of fibroblast growth factor 23 (FGF23), hypophosphatemia and osteomalacia in iron deficient subjects. High levels of FGF23 are associated with increased mortality in the chronic kidney disease (CKD) population. CKD patients are often treated with iv iron therapy in order to maintain iron stores and erythropoietin responsiveness, also in the case of not being iron depleted. Therefore, the effect of a single high iv dose of two different iron preparations, iron isomaltoside 1000 (IIM) and ferric carboxymaltose (FCM), on plasma levels of FGF23 and phosphate was examined in normal and uremic iron repleted rats.

Methods

Iron was administered iv as a single high dose of 80 mg/kg bodyweight and the effects on plasma levels of iFGF23, phosphate, Ca2+, PTH, transferrin, ferritin and iron were examined in short and long term experiments (n = 99). Blood samples were obtained at time 0, 30, 60, 180 minutes, 24 and 48 hours and in a separate study after 1 week. Uremia was induced by 5/6-nephrectomy.

Results

Nephrectomized rats had significant uremia, hyperparathyroidism and elevated FGF23. Iron administration resulted in significant increases in plasma ferritin levels. No significant differences were seen in plasma levels of iFGF23, phosphate and PTH between the experimental groups at any time point within 48 hours or at 1 week after infusion of the iron compounds compared to vehicle.

Conclusions

In non-iron depleted normal and uremic rats a single high dose of either of two intravenous iron preparations, iron isomaltoside 1000, and ferric carboxymaltose, had no effect on plasma levels of iFGF23 and phosphate for up to seven days.

【 授权许可】

   
2013 Gravesen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Disease K, Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012, 2:279-335.
• [2]Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK: Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int 2008, 74:1588-1595.
• [3]Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, et al.: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008, 19:372-379.
• [4]Shirazian S, Grant C, Miller I, Fishbane S: How can Erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Semin Dial 2013, 26:534-536.
• [5]Lim CS, Vaziri ND: The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004, 65:1802-1809.
• [6]Zager RA, Johnson AC, Hanson SY: Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004, 66:144-156.
• [7]Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003, 14:2639-2644.
• [8]Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002, 40:90-103.
• [9]Prats M, Font R, Garcia C, Cabre C, Jariod M, Vea AM: Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post- hoc analysis of a prospective study. BMC Nephrol 2013, 14:167. BioMed Central Full Text
• [10]Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M: Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial 2012, 16:146-151.
• [11]Wolf M, Koch TA, Bregman DB: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013, 28:1793-1803.
• [12]Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, et al.: Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011, 33:421-426.
• [13]Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG: FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009, 94:2332-2337.
• [14]Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al.: Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009, 45:814-816.
• [15]Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al.: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002, 106:2212-2217.
• [16]Martin A, David V, Quarles LD: Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012, 92:131-155.
• [17]Shroff R: Phosphate is a vascular toxin. Pediatr Nephrol 2013, 28:583-593.
• [18]Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G, et al.: Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 2012, 23:1641-1651.
• [19]Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012, 82:737-747.
• [20]Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al.: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
• [21]Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al.: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
• [22]Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al.: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011, 108:E1146-E1155.
• [23]Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ: Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011, 96:3541-3549.
• [24]Wright I, Blanco-Rojo R, Fernandez MC, Toxqui L, Moreno G, Perez-Granados AM, et al.: Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women. J Physiol Biochem 2013, 69:889-896.
• [25]Evstatiev R, Gasche C: Iron sensing and signalling. Gut 2012, 61:933-952.
• [26]Schouten BJ, Doogue MP, Soule SG, Hunt PJ: Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 2009, 46:167-169.
• [27]Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K: Persistent downregulation of calcium- sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol 2002, 13:2110-2116.
• [28]Huan J, Olgaard K, Nielsen LB, Lewin E: Parathyroid hormone 7–84 induces hypocalcemia and inhibits the parathyroid hormone 1–84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 2006, 17:1923-1930.
• [29]Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al.: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
• [30]Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al.: FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010, 21:1125-1135.
• [31]White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MS, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
• [32]Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al.: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
• [33]Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al.: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003, 348:1656-1663.
• [34]Econs MJ, McEnery PT: Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997, 82:674-681.
• [35]Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004, 15 Suppl 2:S93-S98.
• [36]Isakova T, Xie H, Barchi-Chung A, Smith K, Sowden N, Epstein M, et al.: Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol 2012, 7:820-828.
• [37]Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011, 6:383-389.
• [38]Smith ER, Cai MM, McMahon LP, Holt SG: Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 2012, 97:3357-3365.
• [39]Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al.: Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab 2010, 95:E352-E357.